Q-omics provides the consensus-scored SNORA74B profile across patient tissues and cancer cell-line models. SNORA74B expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SNORA74B is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, SNORA74B RNA expression shows 8,847 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UCEC, LIHC, and HNSC as cancer lineages where SNORA74B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA74B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA74B survival associations across molecular data types. SNORA74B RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA74B RNA expression–survival associations across cancer types. High SNORA74B expression shows unfavorable associations in UCEC, LUSC, KIRC and KIRP, but favorable associations in BRCA and MESO. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UCEC as the clearest survival context for SNORA74B RNA expression.
This table summarizes SNORA74B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA74B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA74B shows lower tumor expression in ESCA and higher tumor expression in LIHC, COAD, STAD, BRCA and LUAD. The LIHC box plot shows higher SNORA74B RNA expression in tumor versus normal tissue (log2 FC = +0.320, t-test p = .010).
This table shows molecular features associated with SNORA74B in patient tissues and cancer cell lines. In patient samples, SNORA74B shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
